5 ESSENTIAL ELEMENTS FOR ABBV-744 DRUG DEVELOPMENT PROGRESS AND TIMELINE

In Phase C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Individuals will get treatment until sickness progression or perhaps the contributors are not able to tolerate the study drugs.- Participant eaten grapefruit or grapefruit products and solutions within three days ahead of